Summary:
- This article discusses the development of a new type of cancer immunotherapy that uses engineered T cells to target and destroy cancer cells.
- The therapy involves extracting T cells from a patient, genetically modifying them to recognize and attack specific cancer proteins, and then reinfusing the modified T cells back into the patient.
- Early clinical trials have shown promising results, with some patients experiencing significant tumor regression and improved survival rates, suggesting this approach could be a powerful new tool in the fight against cancer.